--- title: "CNS Pharmaceuticals CEO, Rami Levin, Participates in Virtual Investor CEO Connect Segment Highlighting Company's Recent Strategic Transformation Progress" type: "News" locale: "en" url: "https://longbridge.com/en/news/287072183.md" description: "CNS Pharmaceuticals CEO Rami Levin participated in a Virtual Investor CEO Connect segment, discussing the company's recent $22.5 million financing and strategic transformation. He highlighted progress in pipeline development, key milestones for investors, and the company's growth outlook aimed at enhancing long-term shareholder value." datetime: "2026-05-20T13:10:34.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/287072183.md) - [en](https://longbridge.com/en/news/287072183.md) - [zh-HK](https://longbridge.com/zh-HK/news/287072183.md) generator: "portal-rs" --- # CNS Pharmaceuticals CEO, Rami Levin, Participates in Virtual Investor CEO Connect Segment Highlighting Company's Recent Strategic Transformation Progress ***Access the CEO Connect segment*** ***here*** **HOUSTON, TX / ACCESS Newswire / May 20, 2026 /** CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biotechnology company focused on building a pipeline of innovative therapies addressing significant unmet medical needs, today announced that it participated in a Virtual Investor CEO Connect Segment. As part of the segment, Rami Levin, President and Chief Executive Officer of CNS Pharmaceuticals, highlighted the Company's recent $22.5 million financing, including its strategic pivot, progress made to date and how the capital positions CNS to identify and advance new assets aimed at driving long-term shareholder value. Additionally, Mr. Levin discussed the strategy for pipeline development and securing a new asset, key milestones investors should monitor to evaluate execution of the strategy and the Company's broader growth outlook and investment thesis moving forward. The Virtual Investor CEO Connect segment is accessible here. **About CNS Pharmaceuticals, Inc.** CNS Pharmaceuticals is a biotechnology company focused on developing innovative therapies for serious diseases. With an experienced executive team and a focus on high-value therapeutic opportunities, the Company is working to build a differentiated portfolio of assets addressing significant unmet medical needs. CNS is committed to advancing novel treatments that have the potential to improve patient outcomes while creating long-term value for patients and shareholders. For more information, please visit www.CNSPharma.com, and connect with the Company on X and LinkedIn. **Forward-Looking Statements** Some of the statements in this press release are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995, which involve risks and uncertainties. Forward-looking statements in this release include, without limitation, statements regarding the Company's strategic transformation and pipeline development plans, the anticipated use of proceeds from the Company's recent $22.5 million financing, the Company's ability to identify and advance new therapeutic assets, expectations regarding the Company's ability to create long-term shareholder value, and key milestones related to the execution of the Company's strategy. These statements relate to future events, future expectations, plans and prospects. Although CNS believes the expectations reflected in such forward-looking statements are reasonable as of the date made, expectations may prove to have been materially different from the results expressed or implied by such forward-looking statements. CNS has attempted to identify forward-looking statements by terminology including "believes," "estimates," "anticipates," "expects," "plans," "projects," "intends," "potential," "may," "could," "might," "will," "should," "approximately" or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. These statements are only predictions and involve known and unknown risks, uncertainties and other factors, including market and other conditions and those discussed under Item 1A. "Risk Factors" in CNS's most recently filed Form 10-K filed with the SEC and updated from time to time in its Form 10-Q filings and in its other public filings with the SEC. Any forward-looking statements contained in this press release speak only as of its date. CNS undertakes no obligation to update any forward-looking statements contained in this press release to reflect events or circumstances occurring after its date or to reflect the occurrence of unanticipated events, except as required by law. **CONTACTS:** **Investor Relations Contact** JTC Team, LLC Jenene Thomas 908.824.0775 CNSP@jtcir.com **Business Development Contact** CNS Pharmaceuticals, Inc. Dylan Wenke, Chief Business Officer dwenke@cnspharma.com **SOURCE:** CNS Pharmaceuticals, Inc. View the original press release on ACCESS Newswire ### Related Stocks - [CNSP.US](https://longbridge.com/en/quote/CNSP.US.md) - [IBB.US](https://longbridge.com/en/quote/IBB.US.md) - [BIB.US](https://longbridge.com/en/quote/BIB.US.md) - [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md) - [FBT.US](https://longbridge.com/en/quote/FBT.US.md) - [ARKG.US](https://longbridge.com/en/quote/ARKG.US.md) - [LABU.US](https://longbridge.com/en/quote/LABU.US.md) - [BBH.US](https://longbridge.com/en/quote/BBH.US.md) - [PBE.US](https://longbridge.com/en/quote/PBE.US.md) - [XBI.US](https://longbridge.com/en/quote/XBI.US.md) ## Related News & Research - [Insider Move at CNS Pharmaceuticals Sparks Investor Buzz](https://longbridge.com/en/news/296299014.md) - [CNSP: Strategic pivot targets high-value oncology and neurology assets with strong financial backing](https://longbridge.com/en/news/296126240.md) - [SBIO: U.S. Programmatic and EMEA drove 49% of Q2 sales, with margins rising to 61% and profitability expected in H2 2026](https://longbridge.com/en/news/296517769.md) - [Moderna surges on trial win for cancer shot; William Blair upgrades](https://longbridge.com/en/news/296370751.md) - [Guotai Asset Management sees liquidity boost driving China biotech, innovation drug shares higher](https://longbridge.com/en/news/296448906.md) --- > **Disclaimer: This article is for reference only and does not constitute any investment advice.**